---
schema_version: "secwatch.filing_event.v1"
accession: "0001213900-26-038014"
form_type: "8-K"
ticker: "CVKD"
cik: "0001937993"
company_name: "Cadrenal Therapeutics, Inc."
filed_at: "2026-04-01T23:59:59+00:00"
generated_at: "2026-05-15T08:01:44.301965+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Cadrenal Therapeutics receives $2.5M gross proceeds from warrant exercise, issues new warrants

## Summary
- Existing warrant holder exercises 571,430 shares at reduced price of $4.50 per share, yielding $2.5M gross proceeds.
- Company issues new Series B-1 (5-year term) and Series B-2 (18-month term) warrants to purchase 571,430 shares each at $4.50.
- Placement agent H.C. Wainwright receives 7% cash fee ($175k) and warrants for 37,143 shares at $5.625.
- Expected closing on April 1, 2026; net proceeds used for working capital.
- Company agrees to file resale registration statement for new warrant shares within 30 days.

## SEC filing metadata
- accession: 0001213900-26-038014
- form_type: 8-K
- ticker: CVKD
- cik: 0001937993
- company_name: Cadrenal Therapeutics, Inc.
- filed_at: 2026-04-01T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 1.01, 3.02, 3.03, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1937993/000121390026038014/0001213900-26-038014-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1937993/000121390026038014/ea0284507-8k_cadrenal.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001213900-26-038014
- JSON: https://secwatch.observer/filing/0001213900-26-038014.json
- Plain text: https://secwatch.observer/filing/0001213900-26-038014.txt

## Key facts
- Material Agreements
  Cadrenal Therapeutics, Inc. entered into Inducement Agreement with a holder of Existing Warrants valued at approximately $2.5 million (effective 2026-03-31).
  - Action: entry
  - Agreement: equity purchase
  - Counterparty: a holder of Existing Warrants
  - Value: approximately $2.5 million
  - Effective: 2026-03-31
  source text: On March 31, 2026, Cadrenal Therapeutics, Inc. (the “Company”) entered into a warrant inducement letter agreement (the “Inducement Agreement”) with a holder (the “Holder”) of the Company’s warrants to purchase shares of the Company’s common stock, par value $0.001 per share (the “Common Stock”), issued in a private placement offering that closed on November 4, 2024 (the “Existing Warrants”).
  evidence_url: https://www.sec.gov/Archives/edgar/data/1937993/000121390026038014/0001213900-26-038014-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.